Every day, we handpick the 5 Top Stories stock market investors need to know. In 5 minutes, you’ll learn the stocks, CEOs, and money managers moving markets.
CATL HK HQ
Contemporary Amperex Technology (CATL) [300750:SZ] is to invest HK$1bn in making Hong Kong its international headquarters, and will also establish an R&D centre in the city, Hong Kong Financial Secretary Paul Chan said Thursday. Elsewhere, the firm has denied accusations made by US utility firm Duke Energy [DUK], which said it has disconnected CATL batteries at a Marine Corps base over security concerns.
Can AI Halve Renault’s EV Costs?
The French automaker said on Thursday that it is hoping to cut the cost of producing electric vehicles (EVs) by 50% by 2027 with the help of artificial intelligence (AI). Renault [RNO:PA] also hopes to cut vehicle development times from three to two years. Elsewhere in the EV space, Ford [F] has said that it is unlikely that its Mustang Mach-E will qualify for federal tax credits in January, after the US Treasury issued guidance on new battery sourcing restrictions.
AI Major Disappoints on Earnings
C3.ai Inc. [AI] shares dropped about 9% in extended trading after the firm reported disappointing quarterly revenue, and projected operating losses of some $135m for the fiscal year — far more than analysts’ estimated $87.6m, reported Bloomberg. Elsewhere in AI, on Wednesday Google [GOOGL] released Gemini, the largest and most flexible model the company has yet built. Lastly, the EU is close to finalising its AI regulation: biometric surveillance remains a sticking point.
New AMD Chip Accelerates AI Race
On Wednesday Advanced Micro Devices [AMD] unveiled its new accelerator chips, which it says will be able to run AI software faster than the products of rivals including Nvidia [NVDA]. At the launch, CEO Lisa Su said the AI chip industry could grow to more than $400bn over the next four years, more than double the projection the company made in August.
AbbVie Splashes More Cash
AbbVie [ABBV] is to spend some $8.7bn — paying $45 per share in cash — on Cerevel Therapeutics [CERE], a developer of drugs for neurological conditions including Alzheimer’s. This is AbbVie’s second major deal in a week, as it seeks to make up lost revenue from its arthritis drug Humira: it earlier announced it was to buy cancer drug developer ImmunoGen [IMGN] for $10.1bn.
Disclaimer Past performance is not a reliable indicator of future results.
CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.
CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.
*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.
Continue reading for FREE
- Includes free newsletter updates, unsubscribe anytime. Privacy policy
